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The heart is not traditionally considered either a target or a site of fibroblast growth
factor-21 (FGF21) production. However, recent findings indicate that FGF21 can act as a
cardiomyokine; that is, it is produced by cardiac cells at significant levels and acts in an
autocrine manner on the heart itself. The heart is sensitive to the effects of FGF21, both
systemic and locally generated, owing to the expression in cardiomyocytes of β-Klotho,
the key co-receptor known to confer specific responsiveness to FGF21 action. FGF21 has
been demonstrated to protect against cardiac hypertrophy, cardiac inflammation, and
oxidative stress. FGF21 expression in the heart is induced in response to cardiac insults,
such as experimental cardiac hypertrophy and myocardial infarction in rodents, as well
as in failing human hearts. Intracellular mechanisms involving PPARα and Sirt1 mediate
transcriptional regulation of the FGF21 gene in response to exogenous stimuli. In humans,
circulating FGF21 levels are elevated in coronary heart disease and atherosclerosis, and
are associated with a higher risk of cardiovascular events in patients with type 2 diabetes.
These findings provide new insights into the role of FGF21 in the heart and may offer
potential therapeutic strategies for cardiac disease.
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Introduction
More than a decade has passed since fibroblast growth factor 21 (FGF21), the 21st member
of the FGF family, was identified and cloned. Among FGFs, FGF21 has been shown to be a
secreted protein that acts as a metabolic regulator and plays a role in the control of glucose
homeostasis, insulin sensitivity, and ketogenesis (1, 2). FGF21 expression is under the control of
peroxisome proliferator-activated receptor-α (PPARα), and the main site of its production and
release into the blood is considered to be the liver (1, 3). Extra-hepatic tissues, such as white
and brown adipose tissues and skeletal muscle, also express FGF21 (4–6). Endocrine actions of
FGF21 include the promotion of glucose uptake by white adipocytes through induction of the
glucose transporter, Glut1 (7), activation of brown fat thermogenic activity (8), and promotion
of the appearance of brown fat-like cells in white fat – the so-called “browning” process (9).
FGF21 also has autocrine/paracrine effects, such as induction of hepatic ketogenesis (1). The action
of FGF21 on target cells requires FGF receptors (mainly FGFR1 and FGFR4 in adipose tissue
and liver, respectively) and β-Klotho, a single-pass transmembrane protein that functions as an
obligate cofactor for FGF21 signaling (10, 11). The heart was originally not considered an FGF21
target or source, primarily because of modest expression of mRNA for FGF21 and the transcript
encoding β-Klotho, the obligate co-receptor for cellular responsiveness to FGF21 (12). Intriguingly,
emerging studies have demonstrated that FGF21 is involved in regulating cardiac function. Here,
we review recent advances that have led to the current awareness of the role of FGF21 in cardiac
pathophysiology.
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Cardiac Effects of FGF21
Despite initial evidence excluding the heart as a target tissue of
FGF21, recent studies have demonstrated that FGF21 plays an
important role in cardiac remodeling (13–16). A recent study
from our laboratory provided the first report of the cardiopro-
tective effects of FGF21 (13). This report showed that signifi-
cant amounts of both the FGF21 receptor, FGFR1, and the co-
factor, β-Klotho, are present at the protein level in cardiac cells.
Moreover, treatment of cardiomyocytes in culture with FGF21
was found to activate the extracellular signal-regulated kinase
(ERK) signaling pathway, which is considered the main intracel-
lular pathway responsible for FGF21 intracellular actions. In vivo,
hearts of FGF21-knockout mice exhibit an increase in relative
weight and develop enhanced signs of dilatation. In response
to isoproterenol infusion, a standard model used to induce car-
diac hypertrophy, heart size, and cardiomyocyte volume are
increased to a larger extent in FGF21-knockout mice compared
with control mice. Furthermore, FGF21 treatment prevents car-
diac hypertrophy development (at least, in neonatal mouse mod-
els), enhances fatty acid oxidation, and prevents the induction
of pro-inflammatory pathways in the heart, thereby confirming
the anti-hypertrophic properties of FGF21 (13). An exploration
of the molecular mechanisms underlying these protective effects
of FGF21 further revealed that isoproterenol treatment of FGF21-
knockout mice upregulates pro-inflammatory markers in associa-
tion with a decrease in PPARγ co-activator-1 α (PGC1α) expres-
sion levels. PGC1α is a transcriptional co-activator involved in
the control of energy metabolism and oxidative stress in several
tissues, including the heart (17). It was previously reported that
cardiac expression of PGC1α is repressed by hypertrophic (18)
and pro-inflammatory stimuli (19, 20). In this context, it was
shown that the inhibitory action of FGF21 on cardiac hypertrophy
and inflammation is associatedwith the induction of PGC1α (13).
Moreover, FGF21 was shown to rapidly induce cAMP responsive
element binding protein (CREB) phosphorylation in cardiomy-
ocytes, a finding in accord with previous studies on FGFR1-
mediated induction of CREB in other cell types (21). This lat-
ter effect may explain the observation that FGF21 induces the
expression of PGC1α, a target of CREB (22) and an established
repressor of the NF-κB pro-inflammatory pathway (23). Thus,
this study indicates that FGF21 exerts protective effects against
cardiac hypertrophy through a mechanism involving PGC1α
(Figure 1).
FIGURE 1 | Intracellular mechanisms involved in the control of FGF21
production and action on the heart. In response to cardiac insults,
cardiomyocytes induce the expression of FGF21. To date, one transcriptional
pathway has been implicated in governing this process: the Sirt1–PPARα
pathway. This pathway induces the expression of FGF21, which can be
released by cardiac cells. Moreover, FGF21 acts on the heart, protecting it
from cardiac damage. The molecular mechanisms involved in
FGF21-mediated cardioprotection include activation of the FGF21 receptor,
FGFR1, and the co-factor, β-Klotho, and subsequent activation of the
ERK1/2 pathway. Phosphorylated CREB and p38-MAPK act through
different intracellular mechanisms to exert protection against cardiac
damage.
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Other studies have reported that FGF21 also exerts protection
after myocardial infarction by inhibiting cardiomyocyte apoptosis
(15), attenuating pathological myocardial remodeling, and reduc-
ing infarct size (16, 24). Furthermore, oxidative stress, which also
plays a role in the pathogenesis of heart failure, is modulated by
FGF21 (14). Cardiac FGF21 regulates genes involved in antioxi-
dant pathways, thus preventing the production of reactive oxygen
species (ROS) by cardiac cells. FGF21 induces the expression of
genes encoding proteins involved in antioxidant pathways in car-
diomyocytes in culture, especially uncoupling protein 3 (UCP3)
and superoxide dismutase 2 (SOD2). Furthermore, the expression
of antioxidant genes in response to signals that stimulate pro-
oxidative/pro-inflammatory pathways in the heart is reduced in
FGF21-knockout mice. Taken together, these very recent novel
findings reveal new roles and mechanisms of action of FGF21 in
the heart after myocardial infarction (Figure 1).
Finally, it has been proposed that FGF21 is involved in mod-
ulating cardiac lipid metabolism and homeostasis (25). In fact,
the hormonal factor FGF21 is emerging as a key regulator of
metabolism in general, providing significant health benefits and
protective effects against metabolic disorders associated with obe-
sity, such as insulin resistance, type II diabetes, and dyslipidemias.
Recent initial pilot studies using an FGF21 analog to treat obese
patients have shown promising results (26). Paradoxically, how-
ever, studies in both mice and humans have shown that obesity
is associated with elevated circulating levels of FGF21, suggesting
impaired FGF21 signaling (27–29). Thus, obesity has been pro-
posed as an FGF21-resistance state. This phenomenon of reduced
FGF21 action in obesity has been attributed to an abnormal
reduction in the expression of the FGF21 co-receptor, β-Klotho,
in white adipose tissue, commonly observed in rodent models
of obesity and in obese individuals (30). In obese rats, β-Klotho
protein expression in the heart is reduced, indicating that the
FGF21-resistance state also occurs in the heart (24). Moreover,
FGF21 deletion in mice exacerbates diabetic cardiomyopathy by
aggravating cardiac lipid accumulation, although it is not clear
whether this is a direct effect of the lack of FGF21 action on
heart or indirect due to altered systemic lipid homeostasis in
diabetic FGF21-null mice (31). A recent study has shown that
FGF21 prevents diabetes-induced cardiac apoptosis by activat-
ing the ERK–p38MAPK–AMPK pathway (Figure 1); therefore,
FGF21 has been proposed as a treatment for diabetes-related
cardiac damage (32). Collectively, these data point to FGF21 as
a key regulator of cardiac metabolism and a potential therapeutic
target for the treatment of diabetic cardiomyopathy.
Other research approaches have evidenced mechanisms of
myocardium protection by FGF21 (15).Myocardial ischemia acti-
vates innate protective processes not only in the heart but also in
remote organs. Several recent investigations have demonstrated
that the liver responds to ischemicmyocardial injury by increasing
the secretion of cardioprotective proteins (15, 33). One such pro-
tein identified by microarray-based gene expression profiling and
protein analysis is FGF21 (33, 34), which was found to be highly
increased at the protein level in the liver and also in adipose tissue
after myocardial infarction. The authors of these latter studies
also reported that this secreted FGF21 acts on ischemic cardiomy-
ocytes to mitigate acute myocardial injury. Thus, systemic FGF21
generated mainly by the liver contributes to protection of the
myocardium against ischemic damage.
In summary, current data support the idea that FGF21 acts
directly on cardiac tissue to prevent the development of cardiac
hypertrophy, reduce infarct damage, and attenuate the develop-
ment of diabetic cardiomyopathy in animal models.
Cardiac Production of FGF21
After the demonstration that FGF21 exerts cardioprotective
effects, the next question raised was whether the heart was
also able to endogenously produce FGF21. Our research group
obtained the first data that addressed this question (13) showing
that FGF21 is expressed in and secreted by cells of the heart
in response to different cardiac stress stimuli, such as cardiac
hypertrophy and myocardial infarction. FGF21 secreted by heart
may function in an autocrine manner and, more unlikely, in an
endocrine manner (see below). An analysis of different cell popu-
lations isolated from the heart showed that FGF21 is mainly pro-
duced by cardiomyocytes. Consistent with this, cardiomyocytes
in culture were found to secrete FGF21 protein into the cell cul-
ture medium. Mouse models of experimentally induced cardiac
hypertrophy and myocardial infarction also showed significant
increases in FGF21 expression in the heart. Additional studies
reported increases in cardiac FGF21 expression in obese rats
(24), in type 1 diabetes (32), under fasting conditions (25), after
endoplasmic reticulum (ER) stress (25), and in pro-oxidative/pro-
inflammatory conditions (14). Interestingly, it has been shown
that the human heart is also a source of FGF21, increasing in
patients suffering from heart failure (14). Collectively, these stud-
ies indicate that FGF21 expression is induced in the heart in situ-
ations of pathological (e.g., infarct, hypertrophy) or physiological
(e.g., fasting) stress, suggesting that FGF21 is a cardioprotective
molecule secreted by the heart under conditions of stress.
Insight into the mechanism by which FGF21 gene expression
is regulated in the heart was provided by reports showing that the
Sirt1–PPARα pathway is involved in the transcriptional control of
FGF21 (13, 14). This transcriptional pathway, which is also known
to be involved in the regulation of FGF21 expression in the liver
in the context of the control of carbohydrate and lipid metabolism
(35), was found to play a pivotal role in controlling FGF21 expres-
sion and release in cardiac cells. Studies using genetic mouse
models showed that cardiac FGF21 expression levels are reduced
in PPARα-null mice and Sirt1-null mice compared with wild-
type mice, confirming the involvement of this regulatory pathway
in the control of cardiac FGF21 gene expression. In vitro studies
of cultured cardiomyocytes further showed that inhibition of
PPARα clearly impairs the induction of FGF21 expression caused
by Sirt1 overexpression, indicating that Sirt1 acts through PPARα
(Figure 1).
Recently, cellular stresses, including ER stress and mitochon-
drial dysfunction, have been reported to induce FGF21 expression
and release in several cellular systems, and there are indications
that these same conditions induce FGF21 expression in the heart.
In this context, ER stress inducers, such as the saturated fatty acid
palmitate and the ER stressor tunicamycin, were shown to signif-
icantly increase FGF21 expression in cardiac cells in culture (26).
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Recent findings also underscore the potential role of FGF21 under
conditions of mitochondrial dysfunction, with several studies
showing that skeletalmuscle is an FGF21-producing tissue inmice
(36, 37) and humans (38), and that a mitochondrial respiratory
chain deficiency leads to induction of FGF21 mRNA expression
in skeletal muscle (39). In fact, pharmacological alteration of the
mitochondrial respiratory chain in skeletal muscle cells in cul-
ture strongly induces FGF21 gene expression and FGF21 protein
release into the cell culture medium (37). Moreover, it has been
reported that muscle mitochondrial respiratory chain deficiencies
in human patients are strongly correlated with increased plasma
FGF21 levels (40). In addition, it has been recently reported that,
in mouse cardiac tissue, mitochondrial dysfunction and stress
responses lead to a dramatic – about 300-fold – induction of
FGF21 (41).
The transcription factor, ATF4, might also be involved in the
transcriptional control of cardiac FGF21 expression in response to
mitochondrial dysfunction or ER stress situations (25, 41). Most
studies have proposed that binding of ATF4 to the FGF21 gene
promoter controls FGF21 gene transcription in the heart and in
skeletal muscle in response to signals elicited by mitochondrial
dysfunction and ER stress. However, an ATF4-mediated path-
way of FGF21 induction by mitochondrial dysfunction involving
increased ROS production has been found in skeletal muscle
(36); whether this pathway operates in cardiac cells remains to be
determined.
Although it is thought that the induction of FGF21 expres-
sion and release by skeletal muscle under conditions, such as
pathogenic mitochondrial dysfunction, is responsible, in whole
or in part, for the high systemic levels of FGF21 in patients with
mitochondrial diseases, whether cardiac production of FGF21
results in altered systemic levels in physiological or pathogenic
conditions studied to date remains unknown. The preponderance
of currently available evidence clearly supports an autocrine role
of FGF21 production by the heart.
Cardiac FGF21: Autocrine Versus
Endocrine Actions
The fact that the heart is both a target and a source of FGF21
raises the possibility of a potential autocrine loop for FGF21
in the myocardium. This possibility was first proposed in our
recent study (13), where we showed that FGF21 is expressed in
and secreted by cardiac cells in response to cardiac stress, and
that secreted FGF21 was able to inhibit cardiac damage. This
study demonstrated that the heart locally generates FGF21 via the
Sirt1–PPARα pathway that acts in an autocrine manner to pre-
vent hypertrophy, metabolic dysregulation, and activation of pro-
inflammatory pathways in cardiac tissue. Collectively, the find-
ings of this study describe a new mechanism for controlling car-
diac inflammation and metabolism by locally produced FGF21.
More recently, it was found that autocrine-acting FGF21 released
by cardiomyocytes functions as an antioxidant factor in the heart,
preventing ROS accumulation (14). In this autocrine loop, FGF21
is downstream of Sirt1, which is activated by upstream signals
triggered by FGF21 released into the extracellular space (42).
Thus, FGF21 release by cardiac cells appears to be both a cardiac
response to oxidative stress and a signal to prevent ROS overflow.
Future studies are expected to fill gaps in our current under-
standing of the relationship between oxidative stress and FGF21
expression.
In physiological models of cardiac hypertrophy, such as preg-
nancy (43), the circulating levels of FGF21 (44) as well as FGF21
expression levels in the heart are increased (45). In this physiologi-
cal setting, both autocrine and endocrine cardioprotective roles of
FGF21might be at work. In contrast, in pathological hypertrophy,
circulating levels of FGF21 are unchanged and FGF21 expression
levels are increased only in cardiac tissue, indicating a predom-
inant autocrine role of FGF21 in the heart in this pathological
context (13).
The contribution of cardiac FGF21 production to the systemic
pool remains to be elucidated. The magnitude of FGF21 expres-
sion by the heart compared with that of other tissues known to
contribute to systemic FGF21, such as the liver, is relatively low
(13), although a contribution of cardiac-derived FGF21 in patho-
logical conditions, in which its production is increased, cannot be
excluded. In this context, transgenic mice with cardiac-specific
FGF21 overexpression show increased circulating FGF21 levels
and altered body mass composition (26), suggesting that FGF21
released by the heart has the potential to act at a distance in
an endocrine manner. However, more studies need to be done
to elucidate possible endocrine actions of cardiac FGF21 and its
actual contributions to whole-body homeostasis in physiological
and naturally occurring pathological conditions.
In summary, in addition to the protective role exerted by sys-
temic, circulating FGF21 on the heart, local secretion of FGF21
in the context of cardiac damage may serve as an endogenous,
autoregulatory, cardioprotective signaling pathway. Thus, sys-
temic or locally generated FGF21 acts on the myocardium, pro-
tecting it from cardiac injury (Figure 2).
FGF21 as a Biomarker for Cardiac
Diseases
Several recent clinical studies in humans have explored the role
of FGF21 in cardiovascular diseases. As previously mentioned,
serum levels of FGF21 are elevated in subjects with adverse lipid
profiles, obesity, metabolic syndrome, impaired glucose tolerance,
type 2 diabetes mellitus, and hypertension (47, 48). Elevated
serum FGF21 levels have also been recently reported in subjects
with coronary heart disease or carotid artery plaques indepen-
dently of established cardiovascular risk factors, suggesting its
potential role as a biomarker for atherosclerotic diseases (49–51).
Moreover, plasma FGF21 levels have been linked to a higher risk
of cardiovascular events in patients with type 2 diabetes (52). In
addition, serum FGF21 levels are elevated in atrial fibrillation
patients in association with atrial remodeling (53). Interestingly, a
recent study reported that serum FGF21 levels are independently
associated with acute myocardial infarction (54), showing that
serum FGF21 levels are markedly increased on the first day after
the onset of myocardial infarction and remain high on days 3 and
7; moreover, FGF21 levels were found to be closely related to those
of brain natriuretic protein (BNP), a common marker of cardiac
diseases. The authors of this study concluded that high levels of
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FIGURE 2 | The heart and FGF21 inter- and intra-organ
communication. Several tissues in the organism are potential producers of
FGF21. The main contributor to circulating levels of FGF21 is the liver (46)
and, under most physiological settings, a minor role is played by the white
and brown adipose tissues. After myocardial infarction, liver and white
adipose tissue produce large amounts of FGF21. The heart also produces
increased levels of FGF21 after cardiac insults, such as cardiac hypertrophy,
oxidative stress, and diabetes, among others. The endocrine action of FGF21
released by the liver and possibly by adipose tissues, together with autocrine
FGF21 originating in heart itself, may act to protect against cardiac damage.
The extent to which the heart contributes to systemic FGF21 levels is not yet
fully established.
FGF21 might be related to the incidence of re-infarction within
30 days after onset. Collectively, these studies suggest that FGF21
is a potential new biomarker for cardiac diseases.
Conclusion and Perspectives
Several lines of evidence indicate that communication among
cardiac cells via secreted factors may contribute to myocar-
dial hypertrophic remodeling (55, 56). Recently, the term car-
diomyokine has emerged to describe proteins secreted by the
heart that have autocrine, paracrine, and/or endocrine func-
tions crucial for the maintenance of cardiac function (57).
Cardiomyokines have been estimated to number between 30
and 60, and include growth factors, endocrine hormones, and
cytokines (58, 59). The findings summarized in this review
establish FGF21 as a new cardiomyokine crucial for main-
taining cardiac function. From a biomedical point of view,
the possibility of preventing or even reversing pathologi-
cal cardiac states and thereby slowing the development of
heart disease is of utmost importance. Collectively, the find-
ings summarized here indicate positive effects of FGF21 on the
heart in the context of pathological conditions. Further research
is warranted to explore FGF21 as a tool in the development
of medical strategies to prevent and/or treat cardiac damage as
well for use as a potential biomarker for cardiac diseases. In
any case, the intracellular responses evoked by FGF21 repre-
sent a new rationale for developing a novel treatment modal-
ity based on potentiation of endogenous defenses in diseased
hearts.
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